Upkara is revolutionizing the way biomedical industries tackle cold-chain challenges, not by mitigating them, but by eliminating them. Our innovative biopreservation technology improves access to therapeutics and research tools by enabling ambient temperature storage and transportation. Imagine what you can accomplish when you break free from the cold chain.
Reagents are one of the building blocks upon which all scientific advancements are made. Upkara’s technology not only eliminates the need for temperature-controlled storage of research and diagnostic reagents but also enables the production of easy-to-use, single-use formats.
Biorepositories are an ever-expanding resource used to store a variety of biospecimens, environmental specimens, and research tools, often for decades. Upkara is currently exploring the application of its technology for the use of storing and distributing biospecimens and cells at ambient temperatures.
Therapeutics and vaccines often suffer from temperature-mediated degradation. This results in a need to provide additional stability through lyophilization and/or freezing. In an effort to improve global health equity, Upkara aims to apply its biopreservation technology to therapeutics and vaccines.
Whether your company is designing the next generation of research tools or pharmaceuticals, our no-freeze biopreservation technology saves both time and money–all while reducing waste.
Eliminates expenses related to cold-chain storage and transport
Fewer carbon emissions from cold storage
Significantly faster stabilization than lyophilization
Increased manufactured product yield and reduced product loss due to temperature excursions
Why it matters
Frequently Asked Questions
Our biopreservation technology stabilizes biomolecules without freezing, protecting them from temperature-mediated degradation. This means products can be stored and distributed safely at ambient temperatures, decreasing the need for cold storage and transportation.
Although we have not yet explored every possible application of our technology, we have demonstrated the ability to stabilize antibodies, enzymes, small molecules, and mRNA.
We fully anticipate that our technology can stabilize the same products that lyophilization is currently used for. There is a possibility our technology may stabilize molecules that cannot be lyophilized due to damage caused during the freezing step associated with lyophilization.
We are exploring ways our technology can be used to aid the development and distribution of human health products. Just 10% of healthcare facilities in the world’s poorest countries have access to reliable electricity.
Being able to produce and transport life-saving diagnostic reagents, therapeutics, and vaccines without the need for cold storage would drastically improve global access.